Clinical Policy: Tafasitamab-cxix (Monjuvi)
Reference Number: CP.PHAR.508
Effective Date: 12.01.20
Last Review Date: 11.20
Line of Business: Commercial, HIM, Medicaid

See Important Reminder at the end of this policy for important regulatory and legal information.

Description
Tafasitamab-cxix (Monjuvi®) is a CD19-directed cytolytic antibody.

FDA Approved Indication(s)
Monjuvi, in combination with lenalidomide, is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT).

This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

Policy/Criteria
Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with Centene Corporation® that Monjuvi is medically necessary when the following criteria are met:

I. Initial Approval Criteria
   A. Diffuse Large B-Cell Lymphoma (must meet all):
      1. Diagnosis of relapsed or refractory DLBCL, including DLBCL arising from low grade lymphoma (e.g., follicular lymphoma or nodal marginal zone lymphoma);
      2. Prescribed by or in consultation with an oncologist or hematologist;
      3. Age ≥ 18 years;
      4. Prescribed after prior therapy (see Appendix B) in combination with Revlimid® (lenalidomide) for 12 cycles and subsequently as monotherapy;
         *Prior authorization may be required.
      5. Member is not eligible for ASCT;
      6. Request meets one of the following (a or b):*
         a. Dose does not exceed 12 mg/kg as follows (i, ii, and iii):
            i. Cycle 1: Days 1, 4, 8, 15, and 22 of the 28-day cycle;
            ii. Cycles 2 and 3: Days 1, 8, 15, and 22 of each 28-day cycle;
            iii. Cycle 4 and beyond: Days 1 and 15 of each 28-day cycle;
         b. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence).
         *Prescribed regimen must be FDA-approved or recommended by NCCN
Approval duration: 6 months

B. Other diagnoses/indications
1. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial, HIM.PHAR.21 for health insurance marketplace, and CP.PMN.53 for Medicaid.

II. Continued Therapy
A. All Indications in Section I (must meet all):
1. Currently receiving medication via Centene benefit, or documentation supports that member is currently receiving Monjuvi for a covered indication and has received this medication for at least 30 days;
2. Member is responding positively to therapy;
3. Prescribed in combination with Revlimid®* (lenalidomide) for 12 cycles and subsequently as monotherapy;
   *Prior authorization may be required.
4. If request is for a dose increase, request meets one of the following (a or b):
   a. Dose does not exceed 12 mg/kg as follows (i, ii, and iii):
      i. Cycle 1: Days 1, 4, 8, 15, and 22 of the 28-day cycle;
      ii. Cycles 2 and 3: Days 1, 8, 15, and 22 of each 28-day cycle;
      iii. Cycle 4 and beyond: Days 1 and 15 of each 28-day cycle;
   b. New dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence).
   *Prescribed regimen must be FDA-approved or recommended by NCCN

Approval duration: 12 months

B. Other diagnoses/indications (must meet 1 or 2):
1. Currently receiving medication via Centene benefit and documentation supports positive response to therapy.
   Approval duration: Duration of request or 6 months (whichever is less); or
2. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial, HIM.PHAR.21 for health insurance marketplace, and CP.PMN.53 for Medicaid.

III. Diagnoses/Indications for which coverage is NOT authorized:
A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – CP.CPA.09 for commercial, HIM.PHAR.21 for health insurance marketplace, and CP.PMN.53 for Medicaid or evidence of coverage documents.

IV. Appendices/General Information
Appendix A: Abbreviation/Acronym Key
ASCT: autologous stem cell transplant
DLBCL: diffuse large B-cell lymphoma
FDA: Food and Drug Administration
NCCN: National Comprehensive Cancer Network
Appendix B: Therapeutic Alternatives

This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Dosing Regimen</th>
<th>Dose Limit/Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revlimid (lenalidamide)</td>
<td>25 mg PO on Days 1 to 21 of each 28-day cycle for a maximum of 12 cycles</td>
<td>25 mg/day</td>
</tr>
</tbody>
</table>

**First-Line Treatment Regimens - Examples**

<table>
<thead>
<tr>
<th>Regimen</th>
<th>Dosing Regimen</th>
<th>Dose Limit/Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>RCHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone)</td>
<td>Varies</td>
<td>Varies</td>
</tr>
<tr>
<td>DA-EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin) + rituximab</td>
<td>Varies</td>
<td>Varies</td>
</tr>
<tr>
<td>RCEPP (rituximab, cyclophosphamide, etoposide, prednisone, procarbazine)</td>
<td>Varies</td>
<td>Varies</td>
</tr>
</tbody>
</table>

**Second-Line Treatment Regimens - Examples**

<table>
<thead>
<tr>
<th>Regimen</th>
<th>Dosing Regimen</th>
<th>Dose Limit/Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>GemOx (gemcitabine, oxaliplatin) ± rituximab</td>
<td>Varies</td>
<td>Varies</td>
</tr>
<tr>
<td>CEPP (cyclophosphamide, etoposide, prednisone, procarbazine) ± rituximab</td>
<td>Varies</td>
<td>Varies</td>
</tr>
<tr>
<td>GDP (gemcitabine, dexamethasone, cisplatin) ± rituximab</td>
<td>Varies</td>
<td>Varies</td>
</tr>
</tbody>
</table>

Therapeutic alternatives are listed as Brand name® (generic) when the drug is available by brand name only and generic (Brand name®) when the drug is available by both brand and generic.

Appendix C: Contraindications/Boxed Warnings

None reported.

V. Dosage and Administration

<table>
<thead>
<tr>
<th>Indication</th>
<th>Dosing Regimen</th>
<th>Maximum Dose</th>
</tr>
</thead>
</table>
| DLBCL | Administer premedications prior to starting Monjuvi. 12 mg/kg as an IV infusion according to the following dosing schedule:  
- Cycle 1: Days 1, 4, 8, 15 and 22 of the 28-day cycle.  
- Cycles 2 and 3: Days 1, 8, 15 and 22 of each 28-day cycle.  
- Cycle 4 and beyond: Days 1 and 15 of each 28-day cycle. |
| | Administer Monjuvi in combination with lenalidomide for a maximum of 12 cycles and then continue Monjuvi as monotherapy until disease progression or unacceptable toxicity. | 12 mg/kg/day per dosing schedule |
### Indication | Dosing Regimen | Maximum Dose
---|---|---
| | See prescribing information for premedication and dosing modifications. | |

### VI. Product Availability
Single-dose vial: 200 mg

### VII. References

### Coding Implications
Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

<table>
<thead>
<tr>
<th>HCPCS Codes</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>J3490</td>
<td>Unclassified drugs</td>
</tr>
<tr>
<td>J3590</td>
<td>Unclassified biologics</td>
</tr>
<tr>
<td>J9999</td>
<td>Not otherwise classified, antineoplastic drugs</td>
</tr>
</tbody>
</table>

### Reviews, Revisions, and Approvals
<table>
<thead>
<tr>
<th>Date</th>
<th>P&amp;T Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Policy created</td>
<td>09.02.20</td>
</tr>
</tbody>
</table>

### Important Reminder
This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering
benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage
decisions and the administration of benefits are subject to all terms, conditions, exclusions and
limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy,
contract of insurance, etc.), as well as to state and federal requirements and applicable Health
Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting
may not be the effective date of this clinical policy. This clinical policy may be subject to
applicable legal and regulatory requirements relating to provider notification. If there is a
discrepancy between the effective date of this clinical policy and any applicable legal or
regulatory requirement, the requirements of law and regulation shall govern. The Health Plan
retains the right to change, amend or withdraw this clinical policy, and additional clinical
policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is
not intended to dictate to providers how to practice medicine. Providers are expected to exercise
professional medical judgment in providing the most appropriate care, and are solely responsible
for the medical advice and treatment of members. This clinical policy is not intended to
recommend treatment for members. Members should consult with their treating physician in
connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent
judgment and over whom the Health Plan has no control or right of control. Providers are not
agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and
distribution of this clinical policy or any information contained herein are strictly prohibited.
Providers, members and their representatives are bound to the terms and conditions expressed
herein through the terms of their contracts. Where no such contract exists, providers, members
and their representatives agree to be bound by such terms and conditions by providing services to
members and/or submitting claims for payment for such services.

Note:
For Medicaid members, when state Medicaid coverage provisions conflict with the coverage
provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please
refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2020 Centene Corporation. All rights reserved. All materials are exclusively owned by
Centene Corporation and are protected by United States copyright law and international
copyright law. No part of this publication may be reproduced, copied, modified, distributed,
displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise
published without the prior written permission of Centene Corporation. You may not alter or
remove any trademark, copyright or other notice contained herein. Centene® and Centene
Corporation® are registered trademarks exclusively owned by Centene Corporation.